EHA 2021: Long term results of a study investigating lenalidomide combined with rituximab for treatment of relapsed follicular and mantle cell lymphomas.
Home / Resource Library / Lenalidomide Plus Rituximab Continues to Improve PFS With Manageable Safety in Lymphoma Subtypes